Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care


Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany. This was decided by the Federal Joint Committee (G-BA) with effect from January 8, 2021.

Seed implantation or so...


Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.


Charité Dean Axel Pries to be new president of World Health Summit from 2021 on

Founder Detlev Ganten relinquishes office after 12 years


Alrise announces acquisition of its ImSus® drug delivery technology by Ferring International Center S.A.


The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus®...


Adrenomed closes EUR 22 million equity financing to accelerate development of Adrecizumab (HAM8101) and provides business update

- Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments

- Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4, 2020


COVID-19: Despite the prospect of vaccines, tests are the tool of choice

- Virologists and epidemiologists call for continuous testing to contain the pandemic

- The DiagnostikNet-BB works on many levels of the test chain

- IMDB develops new project family for comprehensive COVID-19 diagnostics


Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline


ProBioGen AG announced the closing of a master service agreement with Asahi Kasei Pharma. As an expert CDMO in high-titer cell line development till large scale GMP manufacturing, ProBioGen will use its proprietary technologies, like the...



Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces 2015229103 entitled “Antibody molecules to LAG- 3 and uses thereof” by the Australian Patent Office.


A new generation of optogenetic tools for research and medicine

The European Research Council (ERC) is providing 10 million euros in funding for an interdisciplinary, collaborative project to structurally and biophysically analyze selected photo-receptors and develop them into “OptoGPCRs”, light-controlled...


Eternygen Announces the First Closing of its Series A2 Funding Round

Eternygen announces today the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment...

Show more items